Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of recombinant human neuregulin for chronic systolic heart failure
CTR20230733Phase 3Active
- Sponsor
- Zensun
- Start
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of neucardin in heart failure with reduced ejection fraction (HFrEF), sponsored by Zensun. Started Jun 2023; status: active.
02
Drugs
neucardin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on CTR20230733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230733.